Ad is loading...
USAQ
Price
$0.09
Change
-$0.00 (-0.00%)
Updated
Nov 21 closing price
XVIPF
Price
$41.23
Change
-$0.00 (-0.00%)
Updated
Nov 21 closing price
Ad is loading...

USAQ vs XVIPF

Header iconUSAQ vs XVIPF Comparison
Open Charts USAQ vs XVIPFBanner chart's image
QHSLab
Price$0.09
Change-$0.00 (-0.00%)
Volume$10K
CapitalizationN/A
Xvivo Perfusion AB
Price$41.23
Change-$0.00 (-0.00%)
Volume$500
CapitalizationN/A
USAQ vs XVIPF Comparison Chart
Loading...
View a ticker or compare two or three
VS
USAQ vs. XVIPF commentary
Nov 23, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is USAQ is a Hold and XVIPF is a Hold.

COMPARISON
Comparison
Nov 23, 2024
Stock price -- (USAQ: $0.09 vs. XVIPF: $41.23)
Brand notoriety: USAQ and XVIPF are both not notable
Both companies represent the Medical Specialties industry
Current volume relative to the 65-day Moving Average: USAQ: 75% vs. XVIPF: 129%
Market capitalization -- USAQ: $698.66K vs. XVIPF: $905.23M
USAQ [@Medical Specialties] is valued at $698.66K. XVIPF’s [@Medical Specialties] market capitalization is $905.23M. The market cap for tickers in the [@Medical Specialties] industry ranges from $3.82T to $0. The average market capitalization across the [@Medical Specialties] industry is $8.03B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

USAQ’s FA Score shows that 0 FA rating(s) are green whileXVIPF’s FA Score has 0 green FA rating(s).

  • USAQ’s FA Score: 0 green, 5 red.
  • XVIPF’s FA Score: 0 green, 5 red.
According to our system of comparison, XVIPF is a better buy in the long-term than USAQ.

Price Growth

USAQ (@Medical Specialties) experienced а -7.61% price change this week, while XVIPF (@Medical Specialties) price change was -1.83% for the same time period.

The average weekly price growth across all stocks in the @Medical Specialties industry was +3.22%. For the same industry, the average monthly price growth was +1.00%, and the average quarterly price growth was -2.22%.

Industries' Descriptions

@Medical Specialties (+3.22% weekly)

Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.

FUNDAMENTALS
Fundamentals
XVIPF($905M) has a higher market cap than USAQ($699K). XVIPF YTD gains are higher at: 80.833 vs. USAQ (-5.556). XVIPF has higher annual earnings (EBITDA): 29.2M vs. USAQ (-473.6K). XVIPF has more cash in the bank: 171M vs. USAQ (93.1K). USAQ has less debt than XVIPF: USAQ (1.63M) vs XVIPF (27.6M). XVIPF has higher revenues than USAQ: XVIPF (524M) vs USAQ (1.24M).
USAQXVIPFUSAQ / XVIPF
Capitalization699K905M0%
EBITDA-473.6K29.2M-2%
Gain YTD-5.55680.833-7%
P/E RatioN/A344.83-
Revenue1.24M524M0%
Total Cash93.1K171M0%
Total Debt1.63M27.6M6%
FUNDAMENTALS RATINGS
USAQ vs XVIPF: Fundamental Ratings
USAQ
XVIPF
OUTLOOK RATING
1..100
2221
VALUATION
overvalued / fair valued / undervalued
1..100
57
Fair valued
89
Overvalued
PROFIT vs RISK RATING
1..100
10050
SMR RATING
1..100
10068
PRICE GROWTH RATING
1..100
6353
P/E GROWTH RATING
1..100
10086
SEASONALITY SCORE
1..100
33n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

USAQ's Valuation (57) in the null industry is in the same range as XVIPF (89). This means that USAQ’s stock grew similarly to XVIPF’s over the last 12 months.

XVIPF's Profit vs Risk Rating (50) in the null industry is somewhat better than the same rating for USAQ (100). This means that XVIPF’s stock grew somewhat faster than USAQ’s over the last 12 months.

XVIPF's SMR Rating (68) in the null industry is in the same range as USAQ (100). This means that XVIPF’s stock grew similarly to USAQ’s over the last 12 months.

XVIPF's Price Growth Rating (53) in the null industry is in the same range as USAQ (63). This means that XVIPF’s stock grew similarly to USAQ’s over the last 12 months.

XVIPF's P/E Growth Rating (86) in the null industry is in the same range as USAQ (100). This means that XVIPF’s stock grew similarly to USAQ’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
RSI
ODDS (%)
Stochastic
ODDS (%)
Momentum
ODDS (%)
MACD
ODDS (%)
TrendWeek
ODDS (%)
TrendMonth
ODDS (%)
Advances
ODDS (%)
Declines
ODDS (%)
BollingerBands
ODDS (%)
Aroon
ODDS (%)
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
CCGEX14.520.08
+0.55%
Calamos Global Equity C
PICMX64.58N/A
N/A
Virtus KAR Mid-Cap Growth I
AGAZX12.79N/A
N/A
Allspring Global Long/Short Equity Inst
DFEMX29.28-0.08
-0.27%
DFA Emerging Markets I
EMOLX16.04-0.05
-0.31%
Lord Abbett Emerging Markets Equity F3

USAQ and

Correlation & Price change

A.I.dvisor tells us that USAQ and XVIPF have been poorly correlated (+23% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that USAQ and XVIPF's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To USAQ
1D Price
Change %
USAQ100%
N/A
XVIPF - USAQ
23%
Poorly correlated
N/A
ADMT - USAQ
21%
Poorly correlated
N/A
WUXIF - USAQ
13%
Poorly correlated
N/A
TDSGF - USAQ
10%
Poorly correlated
N/A
TCHBF - USAQ
7%
Poorly correlated
N/A
More

XVIPF and

Correlation & Price change

A.I.dvisor tells us that XVIPF and USAQ have been poorly correlated (+22% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that XVIPF and USAQ's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To XVIPF
1D Price
Change %
XVIPF100%
N/A
USAQ - XVIPF
22%
Poorly correlated
N/A
NSTM - XVIPF
21%
Poorly correlated
N/A
VYCO - XVIPF
17%
Poorly correlated
-11.99%
ZTEK - XVIPF
9%
Poorly correlated
-4.46%
LUNG - XVIPF
6%
Poorly correlated
+3.55%
More